Background: Osimertinib has been the standard of care in epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). We evaluated outcomes between osimertinib and first/second-generation (1G/2G) EGFR-tyrosine kinase inhibitors (TKIs) as first-line (1L). and investigated how T790M status and sequential osimertinib after 1G/2G EGFR-TKI failure affected overall sur... https://www.remtavares.com/